How Ph.D. was paid
$927,688 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Incentive | Other | Total |
|---|---|---|---|---|---|
| Claire Mazumdar, Ph.D.Chief Executive Officer | $625,000 | — | $292,188 | $10,500 | $927,688 |
| Ryan Cohlhepp, Pharm.D.President and Chief Operating Officer | $588,000 | $10,000 | $249,900 | $10,500 | $858,400 |
| David Raben, M.D.Chief Medical Officer | $525,000 | $5,000 | $170,625 | $8,539 | $709,164 |
What changed and why
- $928KClaire Mazumdar earned total compensation of $927,688 for fiscal year 2025.
- No equity awards were granted to named executive officers during fiscal year 2025 due to IPO-related grants in 2024.
- Annual cash bonuses are determined based on corporate and individual performance achievements.
- Pearl Meyer served as the independent external compensation consultant to the compensation committee.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.